Evidence map›Paper›PMID 26715149›Full record

Trial reportInternational journal of hematology2016

Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.

Katsuhiro Miura, Masaru Nakagawa, Hiromichi Takahashi, Yoshihito Uchino, Hitomi Kodaira, Noriyoshi Iriyama, Masashi Sakagami, Shimon Ohtake, Sumiko Kobayashi, Atsuko Hojo and 6 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Clinical Usefulness of Arbekacin.Infection & chemotherapy · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Katsuhiro MiuraDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan. miura.katsuhiro@nihon-u.ac.jp.
Masaru NakagawaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Hiromichi TakahashiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Yoshihito UchinoDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Hitomi KodairaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Noriyoshi IriyamaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Masashi SakagamiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Shimon OhtakeDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Sumiko KobayashiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Atsuko HojoDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Daisuke KuritaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Yujin KobayashiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Machiko KusudaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Yukio HirabayashiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Yoshihiro HattaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan. hatta.yoshihiro@nihon-u.ac.jp.
Masami TakeiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan.
Nihon University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We performed a clinical trial to investigate the efficacy and safety of arbekacin (ABK), a unique aminoglycoside with activity against methicillin-resistant Staphylococcus aureus (MRSA), in patients with hematological malignancies complicated by high-risk infections. ABK was administered intravenously at a dose of approximately 5 mg/kg with various broad-spectrum β-lactams, followed by therapeutic drug monitoring (TDM). A total of 54 febrile or infectious episodes were registered, and TDM was performed in 44 (81%) cases. The absolute neutrophil count was below 500/μl in 49 (91%) cases, and cytotoxic chemotherapy was being administered in 47 (87%) cases. Before initiation of ABK, 52 (96%) patients had received fluoroquinolones (n = 37) and/or broad-spectrum β-lactams (n = 34). There were 10 cases of documented infections including one of MRSA pneumonia, and 44 cases of febrile neutropenia. The efficacy at the end of treatment was 80% for all patients, and efficacy was significantly higher in patients attaining maximum concentrations ≥ 16 µg/ml or receiving TDM-guided dose-adjustment of ABK (n = 19, 95 vs. 71%, P = 0.039). Renal toxicity was observed in six cases (11%) but was generally acceptable. This study demonstrated that TDM-guided ABK administration may be applicable under limited conditions for patients with hematological malignancies.

Indexed as

AdultAgedAnti-Infective Agentsbeta-LactamsDibekacinDrug MonitoringDrug Therapy, CombinationFebrile NeutropeniaFemaleFluoroquinolonesHematologic NeoplasmsHumansInfusions, IntravenousMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedAnti-Infective Agentsarbekacinbeta-LactamsDibekacinFluoroquinolonesArbekacinCoagulase-negative StaphylococciFebrile neutropeniaMethicillin-resistant Staphylococcus aureusTherapeutic drug monitoringVancomycin

Identifiers

PMID26715149
OpenAlexW2197370158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.